Barrick Gold, the Canadian mining major, has announced that it is set to resume operations at its site in Papua New Guinea after receiving a special mining lease from Governor General Bob Dabae. This approval has cleared the way for the New Porgera joint venture, in which Papua New Guinean stakeholders own a 51% stake and Barrick Niugini holds the remaining 49%, to restart production at the gold mine.
The Porgera mine has been under care and maintenance for the past three years. Now, with the granting of the mining lease, the next important step for the joint venture is to engage with the mine property's landowners in order to finalize compensation agreements. Barrick Gold's Chief Executive, Mark Bristow, has expressed confidence that a resolution on compensation can be reached in the coming week. Once these agreements are in place, the company plans to accelerate recruitment initiatives to quickly staff up for operations to ramp up before the end of this year.
This development signifies a positive outlook for Barrick Gold and the Porgera gold mine as they work towards resuming full-scale production. With careful negotiation and agreement on compensation, the company aims to bring the mine back online, benefiting both local stakeholders and Barrick Gold as a whole.
Groupon Shares Surge
Related Articles
![Doctors Rally in Seoul in Support of Striking Juniors](https://www.signalsforex.net/img/0888b08e-b978-43c0-bdb4-4db1785eb1d5/news-article-3.jpeg?fm=jpg&q=80&fit=max&crop=1440%2C1080%2C240%2C0)
Doctors Rally in Seoul in Support of Striking Juniors
Senior doctors in South Korea support junior doctors on strike against government's plan to raise medical school admissions, facing threats and criticism. Publi...
![BridgeBio Pharma Inc. Reports Positive Results in Late-Stage Trial](https://www.signalsforex.net/img/0888b08e-b978-43c0-bdb4-4db1785eb1d5/news-article-3.jpeg?fm=jpg&q=80&fit=max&crop=1440%2C1080%2C240%2C0)
BridgeBio Pharma Inc. Reports Positive Results in Late-Stage Trial
BridgeBio Pharma Inc. reports positive results in a late-stage trial for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The trial achieves sta...
![Novavax Stock Decline](https://www.signalsforex.net/img/0888b08e-b978-43c0-bdb4-4db1785eb1d5/news-article-3.jpeg?fm=jpg&q=80&fit=max&crop=1440%2C1080%2C240%2C0)
Novavax Stock Decline
Novavax's fourth-quarter results fall short, with revenue decrease and lower than expected losses. CEO highlights progress in transition year despite challenges...